Method for determining risk of developing normal tension glaucoma specific to koreans caused by single nucleotide polymorphism

By genotyping specific SNPs in the SIX1/SIX6 locus, the method effectively predicts the risk of normal tension glaucoma in Koreans, addressing the unclear association and providing a biomarker for reduced risk, thereby improving diagnostic accuracy.

WO2024248577A1PCT designated stage expired Publication Date: 2024-12-05THE CATHOLIC UNIV OF KOREA IND ACADEMIC COOP FOUND
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/095178
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-08-02
Filing Date
2024-02-15
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current methods fail to accurately predict the risk of developing normal tension glaucoma in Koreans, as the association between the SIX1/SIX6 locus and normal tension glaucoma is unclear, and existing studies have inconsistent definitions of open-angle glaucoma patients.

Method used

The method involves genotyping specific single nucleotide polymorphisms (SNPs) such as rs10483727 and rs33912345 in the SIX1/SIX6 locus to determine the genetic susceptibility of normal tension glaucoma, using TaqMan single nucleotide polymorphism genotyping, and employing biomarker compositions and kits to detect these SNPs for risk prediction.

Benefits of technology

The method significantly associates the SIX1/SIX6 locus SNPs with the risk of normal tension glaucoma, providing a biomarker for reduced risk determination, with minor alleles showing protective effects, and enabling accurate prediction of normal tension glaucoma risk in Koreans.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000001
    Figure 000001
  • Figure 000002
    Figure 000002
  • Figure 000003
    Figure 000003
Patent Text Reader

Abstract

The present invention relates to a method for analyzing the risk of developing normal tension glaucoma in Koreans by a single nucleotide polymorphism (SNP) and, more specifically, relates to: a method for identifying, from a biological sample, one or more SNPs selected from the group consisting of rs10483727 and rs33912345; a biomarker composition for detecting normal tension glaucoma in Koreans, comprising an SNP; a composition for predicting the risk of developing normal tension glaucoma, comprising an agent capable of detecting the biomarker composition; and a kit for predicting the risk of developing normal tension glaucoma, comprising the composition. According to the present invention, it is possible to provide information useful for predicting the risk of developing normal tension glaucoma in Koreans on the basis of SNPs. In particular, such information can be more conveniently provided by using the kit of the present invention.
Need to check novelty before this filing date? Find Prior Art

Description

A Korean-specific method for assessing the risk of developing normal-tension glaucoma based on single-nucleotide polymorphisms

[0001] The present invention relates to a method for analyzing the risk of developing normal tension glaucoma in Koreans using a single nucleotide polymorphism.

[0002] Glaucoma is a degenerative and progressive optic neuropathy characterized by glaucomatous optic nerve damage accompanied by visual field defects. Glaucoma is a leading cause of visual field loss and blindness worldwide. Recent studies have revealed that open-angle glaucoma (OAG) is phenotypically and genetically heterogeneous and is essentially polygenic.

[0003] Increased intraocular pressure (IOP) is not a necessary criterion for diagnosing glaucoma. In Koreans, normal tension glaucoma (NTG) is the most common subtype of glaucoma. Studies across various ethnic groups suggest that NTG and NTG share some genetic risk factors, but the association with glaucoma may differ depending on genetic variation.

[0004] Previous studies have reported that the SIX1 / SIX6 locus is associated with open-angle glaucoma (OAG) in various ethnicities. However, the definition of OAG patients varied among studies, and the association of the SIX1 / SIX6 locus with normal tension glaucoma (NTG) in Koreans remains uncertain.

[0005] Accordingly, the inventor of the present invention investigated the association between the incidence of normal tension glaucoma and the SIX1 / SIX6 gene locus in a Korean cohort and attempted to use the association to predict or diagnose normal tension glaucoma. The inventor confirmed that SIX1 / SIX6, an OAG-related SNP, was significantly associated with normal tension glaucoma, and completed the present invention.

[0006] The purpose of the present invention is to provide a method for determining at least one single nucleotide polymorphism (SNP) selected from the group consisting of rs10483727 and rs33912345 from a biological sample in order to provide information necessary for predicting the risk of developing normal tension glaucoma in Koreans.

[0007] Another object of the present invention is to provide a biomarker composition for determining normal tension glaucoma in Koreans, comprising at least one single nucleotide polymorphism (SNP) selected from the group consisting of rs10483727 and rs33912345.

[0008] Another object of the present invention is to provide a composition for predicting the risk of developing normal tension glaucoma, comprising a preparation capable of detecting the biomarker composition.

[0009] Another object of the present invention is to provide a kit for predicting the risk of developing normal tension glaucoma, comprising the composition.

[0010] Other objects and advantages of the present invention will become more apparent from the detailed description, claims and drawings below.

[0011] We investigated the association between normal-tension glaucoma (NTG) and the SIX1 / SIX6 locus in a Korean cohort and confirmed that SIX1 / SIX6 locus polymorphisms are significantly associated with genetic susceptibility to NTG in Koreans. To this end, four polymorphisms in the SIX1 / SIX6 locus (rs33912345, rs12436579, rs2179970, and rs10483727) were genotyped in 327 subjects using TaqMan single-nucleotide polymorphism genotyping.

[0012] In addition, the rs33912345 polymorphism was significantly associated with NTG in the recessive model (odds ratio (OR): 0.265; 95% confidence interval (CI): 0.078–0.898, P =0.033)), but not in the allelic and dominant models (both P >0.05). SNP rs10483727 was significantly associated with NTG in the allelic model (OR: 0.674; 95% CI: 0.464–0.979, P =0.038) and the recessive model (OR: 0.187; 95% CI: 0.058–0.602, P =0.005). However, genetic association analysis of SNPs rs12436579 and rs2179970 revealed no significant differences in genotype distributions between NTG cases and controls under either the allele, dominant, or recessive models (all P >0.05). Therefore, we confirmed that the SIX1-SIX6 loci rs10483727 and rs33912345 polymorphisms are significantly associated with the risk of developing NTG in Koreans.

[0013] The present invention provides a method for determining at least one single nucleotide polymorphism (SNP) selected from the group consisting of rs10483727 and rs33912345 from a biological sample in order to provide information necessary for predicting the risk of developing normal tension glaucoma in Koreans.

[0014] In the present invention, polymorphism refers to the case where two or more alleles exist at a single locus, and among the polymorphic sites, a single nucleotide polymorphism (SNP) that differs only by a single base from person to person is called a single nucleotide polymorphism. A preferred polymorphic marker has two or more alleles that exhibit an occurrence frequency of 1% or more, more preferably 5% or 10% or more, in a selected population. Therefore, genetic association for a polymorphic marker means that there is an association for one or more specific alleles of a specific polymorphic marker. The marker may include any variant form of allele found in the genome, including single nucleotide polymorphisms (SNPs), microsatellites, insertions, deletions, duplications, and translocations.

[0015] In the present invention, an allele or biallelic trait refers to multiple types of a gene existing at the same locus on a homologous chromosome. The term allele is also used to indicate polymorphism; for example, a single nucleotide polymorphism (SNP) has two types of alleles.

[0016] In the present invention, "rs_id" refers to an independent marker, rs-ID, assigned to all initially registered SNPs by NCBI, which began accumulating SNP information in 1998. In the present invention, it is described in the form rs10483727. The rs_id described in this table refers to the SNP marker, which is a polymorphic marker of the present invention. Those skilled in the art will be able to easily identify the location and sequence of the SNP using the rs_id.

[0017] In the present invention, rs10483727 and rs33912345, which are used to predict the risk of developing normal tension glaucoma in Koreans, are each registered in the single nucleotide polymorphism database of the National Center for Biotechnology Information (NCBI dbSNP, http: / http: / www.ncbi.nlm.nih.gov / snp / ).

[0018] Meanwhile, carriers of the AA genotype for rs33912345 or the CC genotype for rs10483727 were identified as having a reduced risk of normal tension glaucoma (NTG). Specifically, minor alleles for two SNPs in SIX1 / SIX6 exhibited protective effects, with a lower frequency in NTG patients than in controls. According to one embodiment of the present invention, since AA genotype carriers for the rs33912345 appear at a higher rate in the control group than in the patient group, it is determined that the Minor allele (A) has a protective effect, and since CC genotype carriers for the rs10483727 appear at a higher rate in the control group than in the patient group, it is determined that the Minor allele (C) has a protective effect.

[0019] In the present invention, the single nucleotide polymorphism of rs33912345 may be determined by a recessive model, and the single nucleotide polymorphism of rs10483727 may be determined by an allelic model or a dominant model.

[0020] In the present invention, the single nucleotide polymorphism (SNP) may be located in the intergenic region between the SIX1 and SIX6 gene loci.

[0021] In the present invention, the biological sample may be blood, tissue, cells, serum, plasma, saliva, urine, etc., but is not limited thereto.

[0022] In the present invention, the subject of the biological sample may be a Korean.

[0023] In addition, the present invention provides a biomarker composition for determining normal tension glaucoma in Koreans, comprising at least one single nucleotide polymorphism (SNP) selected from the group consisting of rs10483727 and rs33912345.

[0024] In addition, the present invention provides a composition for predicting the risk of developing normal tension glaucoma, comprising a preparation capable of detecting the biomarker composition.

[0025] In the present invention, the agent capable of detecting the biomarker composition may be, but is not limited to, a primer or probe that specifically binds to a polynucleotide including a SNP marker or a complementary polynucleotide thereof.

[0026] In the present invention, the primer or probe that specifically binds to the polynucleotide or its complementary polynucleotide is allele-specific.

[0027] In the present invention, a primer refers to a short nucleic acid sequence with a short free hydroxyl group that can form base pairs with a complementary template and serves as a starting point for copying the template strand. The primer of the present invention can be chemically synthesized using a method known in the art, such as, for example, a phosphoramidite solid support method.

[0028] In the present invention, the probe refers to a nucleic acid fragment such as RNA or DNA consisting of several to several hundred bases that can specifically bind to mRNA and is labeled so as to confirm the presence or absence of a specific mRNA. The probe can be produced in the form of an oligonucleotide probe, a single-stranded DNA probe, a double-stranded DNA probe, an RNA probe, etc., and can be labeled with biotin, FITC, rhodamine, DIG, etc., or labeled with a radioisotope, etc.

[0029] In the present invention, the probe may be labeled with a detectable substance, for example, a radioactive label that provides a suitable signal and has a sufficient half-life. The labeled probe may be hybridized to a nucleic acid on a solid support, as described in the literature (Sambook et al., Molecular Cloning, A Laboratory Manual, 1989).

[0030] In the present invention, the probe is an allele-specific probe, and due to the presence of a polymorphic site in the nucleic acid fragment, the probe may hybridize to a nucleic acid fragment containing one allele but not to a nucleic acid fragment containing the other allele. In this case, the hybridization conditions must be sufficiently stringent to ensure a significant difference in hybridization intensity between the alleles and to hybridize only to one of the alleles. Preferably, the probe may be single-stranded to maximize hybridization efficiency, but is not limited thereto.

[0031] In the present invention, detection of a specific nucleic acid using the primer can be performed by amplifying the sequence of the target gene using an amplification method such as PCR, and then confirming whether the gene has been amplified using a method known in the art. Furthermore, detection of a specific nucleic acid using a probe can be performed by contacting a sample nucleic acid with the probe under suitable conditions and then confirming the presence of a hybridized nucleic acid.

[0032] In the present invention, methods for detecting a specific nucleic acid using the probe or primer include, but are not limited to, polymerase chain reaction (PCR), DNA sequencing, RT-PCR, primer extension (Nikiforeov et al., Nucl Acids Res 22, 4167-4175, 1994), oligonucleotide extension analysis (Nickerson et al., Pro Nat Acad Sci USA, 87, 8923-8927, 1990), allele-specific PCR (Rust et al., Nucl Acids Res, 6, 3623-3629, 1993), RNase mismatch cleavage (RNase mismatch cleavage, Myers et al., Science, 230, 1242-1246, 1985), single strand conformational polymorphism (single strand conformational polymorphism, Orita et al., Pro Nat Acad Sci USA, 86, 2766-2770, 1989), simultaneous SSCP and heteroduplex analysis (Lee et al., Mol Cells, 5:668-672, 1995), denaturing gradient gel electrophoresis (DGGE, Cariello et al., Am J Hum Genet, 42, 726-734, 1988), denaturing high pressure liquid chromatography (Underhill et al., Genome Res, 7, 996-1005, 1997), hybridization reactions, DNA chips, etc. Examples of the above hybridization reactions include Northern hybridization (Maniatis T. et al., Molecular Cloning, Cold Spring Harbor Laboratory, NY, 1982), in situ hybridization (Jacquemier et al., Bull Cancer, 90:31-8, 2003), and microarray (Macgregor, Expert, Rev Mol Diagn 3:185-200, 2003) methods.

[0033] In addition, the present invention provides a kit for predicting the risk of developing normal tension glaucoma, comprising the composition.

[0034] In the present invention, the kit may include a polynucleotide, primer or probe for identifying one or more markers among polymorphic markers, as well as one or more other component compositions, solutions or devices suitable for the analysis method.

[0035] In the present invention, the kit may be a kit containing essential elements necessary for performing PCR. In addition to a specific polynucleotide, primer, or probe for the polymorphic marker, the PCR kit may include a test tube or other appropriate container, a reaction buffer (with various pH and magnesium concentrations), deoxynucleotides (dNTPs), enzymes such as Taq polymerase and reverse transcriptase, DNase, RNAse inhibitor, DEPC water, and sterile water.

[0036] According to the present invention, there is an advantage in that it can be usefully used to predict the risk of developing normal tension glaucoma in Koreans based on single nucleotide polymorphisms.

[0037] Hereinafter, to aid understanding of the present invention, examples will be given in detail. However, the following examples are intended only to illustrate the scope of the present invention and are not intended to limit its scope. These examples are provided to more fully explain the present invention to those of average skill in the art.

[0038]

[0039] Example 1. Experimental method

[0040]

[0041] 1.1 Study group selection

[0042]

[0043] Unrelated NTG patients and healthy controls were recruited from the Department of Ophthalmology, Uijeongbu St. Mary's Hospital, South Korea. All subjects provided written informed consent after receiving an explanation of the purpose of genetic testing and the blood collection process. Those who refused participation were excluded. The study was approved by the Institutional Review Board of Uijeongbu St. Mary's Hospital, South Korea (Approval Number: UC16SISE0060), and the study was conducted in accordance with the principles of the Declaration of Helsinki.

[0044] A thorough ophthalmologic examination, including optic nerve head examination, was performed on all participants. Inclusion criteria were as follows: a characteristic glaucomatous optic nerve head with a VCDR ≥0.6; diffuse or focal neuroretinal rim thinning (e.g., notching or acquired optic disc notch) and / or retinal nerve fiber layer (RNFL) defects; glaucomatous visual field defects measured with a Humphrey automated field analyzer (Zeiss Humphrey Systems, Dublin, CA); open angle structure; and medication-free IO1 ≤21 mmHg at the initial examination and repeat measurements on different days.

[0045] Glaucomatous visual field defect was defined as a cluster of three or more points with a probability of <5% or a probability of <5% on the pattern deviation map in at least one hemifield with at least one point with a probability of <1%, and a field outcome of "normal limits on the external glaucoma hemifield test" or a pattern standard deviation with a probability of <5%.

[0046] A total of 210 NTG patients (80 men, 130 women) with a mean age of 67.15 ± 12.8 years met the inclusion criteria. Patients with angle-closure glaucoma, pigmentary glaucoma, uveitic glaucoma, neovascular glaucoma, or a history of trauma were excluded. Control subjects (117 patients, 46 men, 71 women; mean age 70.3 ± 10.9 years) met the following criteria at recruitment: normal optic nerve head; normal IOP (≤21 mm Hg); no history of elevated IOP; and no family history of glaucoma.

[0047]

[0048] 1.2 Sample preparation and allele determination

[0049]

[0050] Genomic DNA was isolated from blood using the MG Blood Genomic DNA Extraction SV kit (MGmed, Seoul, Korea). Four SNPs (rs33912345, rs12436579, rs2179970, and rs10483727) in the SIX1 / SIX6 locus were analyzed in the present invention.

[0051] Genotyping for the rs33912345, rs12436579, rs2179970, and rs10483727 polymorphisms was performed with a QuantStudio real-time polymerase chain reaction system (Applied Biosystems) using TaqMan SNP Genotyping Assay assay IDs of C___2485201_10, C__11916555_30, C__15840320_10, and C___2485225_20 (Applied Biosystems, Foster City, CA), respectively.

[0052]

[0053] 1.3 Statistical Analysis

[0054]

[0055] Statistical analyses were performed to investigate the association between SIX1-SIX6 SNPs and susceptibility to NTG. The four major SNPs were tested for Hardy-Weinberg equilibrium using the χ2 test. Frequencies and odds ratios (ORs) with 95% confidence intervals (CIs) for all polymorphic SNPs were calculated. Comparisons of genotype and allele frequencies were performed using the χ2 test or Fisher exact test. Allelic associations were assessed by logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs).

[0056] SNP associations were tested using three genetic models: a dominant model (common allele homozygote (AA) vs. heterozygote (AB) + minor allele homozygote (BB)), a recessive model (AA+AB vs. BB), and an allelic model (A vs. B). All statistical analyses were performed using R software (R Foundation for Statistical Computing, Vienna, Austria). A P value of <0.05 was considered statistically significant in all association analyses.

[0057]

[0058] Example 2. Experimental Results

[0059]

[0060] To assess the possible association between NTG and the SIX1 / SIX6 loci, we performed genotyping of four single nucleotide polymorphisms (SNPs) in a Korean cohort. The study included 327 subjects (210 NTG patients and 117 healthy controls). For each SNP, genotypes were in Hardy-Weinberg equilibrium in all controls (Table 1). Table 1 presents general information about the four SNPs.

[0061]

[0062] SNP genotype (major / minor) base position (GRCh38) p_HWE control rs33912345C / A605098190.981 rs12436579C / A605163690.861 rs2179970G / C605875070.970 rs10483727T / C606061570.296

[0063] MAF, minor allele frequencies; p_HWE, p_Hardy-Weinberg equilibrium; SNP, single-nucleotide polymorphism

[0064]

[0065] Additionally, the association results of the four SNPs in the allelic model, dominant model, and recessive model are summarized in Table 2.

[0066]

[0067] Allele modelDominant modelRecessive modelSNPMAF (C case / Control)GenotypeCase, N (%)Control, N (%)POR (95% CI)POR (95% CI)POR (95% CI)rs339123450.222 (0.200 / 0.261)CC130 (61.9)64 (54.7)0.0740.709 (0.486-1.034)0.2040.743 (0.470-1.175)0.0330.265 (0.078-0.898)CA76 (36.2)45 (38.5)AA4 (1.9)8 (6.8)rs124365790.324 (0.302 / 0.363)CC102 (48.6)47 (40.2)0.1110.760 (0.542-1.066)0.1440.711 (0.450-1.124)0.2860.676 (0.330-1.387)CA89 (42.4)55 (47.0)AA19 (9.0)15 (12.8)rs21799700.096 (0.098 / 0.094)GG171 (81.4)96 (82.1)0.8811.042 (0.605-1.797)0.8891.043 (0.580-1.874)0.9291.115 (0.100-12.434)GC37 (17.6)20 (17.1)CC2 (1.0)1 (0.9)rs104837270.228 (0.202 / 0.274)TT129 (61.4)64 (54.7)0.0380.674 (0.464-0.979)0.2360.758 (0.480-1.199)0.0050.187 (0.058-0.602)TC77 (36.7)42 (35.9)CC4 (1.9)11 (9.4)

[0068] Significant SNPs and P-values ​​are shown in bold. CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single-nucleotide polymorphism.

[0069]

[0070] A significant association between rs33912345 and NTG was confirmed using the recessive model (OR: 0.265; 95% CI: 0.078-0.898, P=0.033), but no significant association between rs33912345 and NTG was observed using the dominant or allelic model (P=0.204 or 0.064, respectively, Table 2).

[0071] A significant association between rs10483727 and NTG was confirmed using the recessive and allelic models (OR: 0.187; 95% CI: 0.058-0.602, P=0.005 and OR: 0.674; 95% CI: 0.464-0.979, P=0.038, respectively), but no significant association between rs10483727 and NTG was found using the dominant model (P=0.236, Table 2).

[0072] Genetic association analysis for rs12436579 and rs2179970 did not reveal statistically significant differences in genotype distribution between NTG patients and control subjects under allelic, dominant, or recessive models (all P > 0.05 Table 2).

[0073] Furthermore, carriers of the AA genotype for rs33912345 and the CC genotype for rs10483727 were found to have a reduced risk of NTG. We found that the rs10483727 polymorphism was significantly associated with an increased NTG risk in both recessive and allelic models.

[0074]

[0075] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A method for determining one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of rs10483727 and rs33912345 from a biological sample to provide information necessary for predicting the risk of developing normal tension glaucoma in Koreans.

2. In paragraph 1, A method in which the single nucleotide polymorphism of rs33912345 is determined by a recessive model, and the single nucleotide polymorphism of rs10483727 is determined by an allelic model or a dominant model.

3. In paragraph 1, A method wherein the risk of normal tension glaucoma is determined to be reduced in those who are AA genotype carriers for rs33912345 or CC genotype carriers for rs10483727.

4. In paragraph 1, A method wherein the above single nucleotide polymorphism (SNP) is located in the intergenic region between the SIX1 and SIX6 gene loci.

5. In paragraph 1, A method, characterized in that the biological sample is any one selected from the group consisting of blood, tissue, cells, serum, plasma, saliva, and urine.

6. In paragraph 1, A method characterized in that the subject of the above biological sample is Korean.

7. A biomarker composition for determining normal tension glaucoma in Koreans, comprising at least one single nucleotide polymorphism (SNP) selected from the group consisting of rs10483727 and rs33912345.

8. A composition for predicting the risk of developing normal tension glaucoma, comprising a preparation capable of detecting the biomarker composition of Article 7.

9. A kit for predicting the risk of developing normal tension glaucoma, comprising the composition of Article 8.

Citation Information

Patent Citations

  • Ophthalmic disease-related SNP site primer composition and use thereof

    CN113403379A

  • Gene sensitive to normal-tension glaucoma disease, and use thereof

    KR1020110094041A

  • Methods and compositions for the treatment of glaucoma

    US20170072025A1